OTC Norgestrel Widens Access as Pharmacists Guide Use

More than 2 years after the FDA approved norgestrel (Opill; Perrigo) as the first nonprescription daily oral contraceptive, new cross-sectional data confirm the drug is reaching the very populations it was meant to help—uninsured individuals, rural residents, and younger patients who previously used no contraception or less-effective methods.

For pharmacists, who are often the first and sometimes only clinician a patient interacts with when buying norgestrel off the shelf, the finding sharpens an already central counseling role around daily dosing, missed pills, and when to seek further care.^1,2

What the Access Data Show

In a cross-sectional study of 986 oral contraceptive users aged 15 to 45 across 31 states, published in JAMA Network Open, individuals who accessed OTC contraception were significantly more likely than prescription users to be uninsured (31.6% vs 3.5%) and to live in rural areas (14.4% vs 8.4%).

OTC users accounted for 320 participants (32.5%) of the sample, and the largest share overall was aged 20 to 24 years (338 participants, 34.3%). OTC access was associated with a 31.8 percentage-point increase in individuals shifting from no method to an effective method (95% CI, 24.1-39.5 percentage points) and a 41.0 percentage-point increase in transitioning from less-effective methods (95% CI, 33.8-48.1 percentage points). The authors noted that lack of insurance and rural residence are two of the main barriers people face in accessing any health care.²

The affordability case reinforces the access story: norgestrel is priced at roughly $19.99 for a 28-day pack, with larger multi-month packs available, making it an option for patients who lack coverage for prescription contraception.³

Why Progestin-Only Dosing Demands Counseling

Norgestrel is a progestin-only pill (POP) containing 0.075 mg per tablet, with no estrogen component, and it must be taken at the same time every day for maximum efficacy. Because POPs are less forgiving of missed or delayed doses than combined oral contraceptives, adherence is the single most important determinant of effectiveness and the point where pharmacist counseling delivers the most value.

Pharmacists can reinforce that a dose taken more than 3 hours late is treated as a missed pill per FDA labeling, requiring a backup method such as a condom for the next 48 hours. Suggesting practical adherence support—alarms, apps, or anchoring the dose to a daily habit—can help patients maintain the narrow dosing window.^1,3

The Pharmacist's Expanded Role at the Counter

With no prescriber in the loop, pharmacists educate, screen for the few contraindications, and set expectations for side effects. Currently, breast cancer is the primary absolute contraindication; patients with any other cancer should consult a physician before use. Pharmacists can preempt the most common reason patients discontinue—irregular bleeding, spotting, or prolonged bleeding—by counseling that these effects are expected and not a reason to stop. Other common side effects include headache, dizziness, nausea, increased appetite, and abdominal cramping.¹

Counseling should also correct predictable misunderstandings: norgestrel is not emergency contraception and does not protect against HIV or other sexually transmitted infections, so condoms remain necessary for sexually transmitted infection (STI) prevention. Pharmacists should advise patients to take a pregnancy test and consult a clinician if they miss 2 periods or miss 1 period alongside missed doses and to seek care for repeated bleeding after sex or prolonged bleeding.

Finally, pharmacists are well positioned to encourage continued reproductive care—STI testing and preventive exams—that OTC purchasing might otherwise displace.¹

REFERENCES

1. FDA approves first nonprescription daily oral contraceptive. News release. FDA. Released July 13, 2023. Accessed August 26, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive

2. Rodriguez MI, Burns H, Sheridan R, Edelman AB. Over-the-counter oral contraceptive use and initiation of contraception. JAMA Netw Open. 2025;8(8):e2527438. doi:10.1001/jamanetworkopen.2025.27438

3. Chandra R, Massey R. What you should know about norgestrel, an OTC birth control option. Pharmacy Times. Published October 10, 2024. Accessed August 26, 2026. https://www.pharmacytimes.com/view/what-you-should-know-about-norgestrel-an-otc-birth-control-option